The Journey to Hepatitis C Elimination in Taiwan: Insights From the Hemodialysis Population - Takeaways - MDSpire

The Journey to Hepatitis C Elimination in Taiwan: Insights From the Hemodialysis Population

  • By

  • Ming-Yan Jiang

  • Yi-Chan Lee

  • Tsung-Hsueh Lu

  • January 29, 2026

  • 0 min

Share

  • 1

    Hemodialysis patients in Taiwan are prioritized for hepatitis C virus (HCV) elimination due to high prevalence and end-stage kidney disease burden.

  • 2

    Direct-acting antivirals (DAAs) have significantly improved HCV treatment rates among hemodialysis patients in Taiwan.

  • 3

    The study found that only 48.2% of HCV antibody-positive patients underwent confirmatory RNA testing, indicating a major gap in care.

  • 4

    Cumulative DAA treatment rates increased from 10% before 2018 to 73.4% by 2021, highlighting progress in HCV management.

  • 5

    Addressing the gap in RNA testing is essential for sustaining progress towards HCV elimination in Taiwan's hemodialysis population.

Original Source(s)

The Journey to Hepatitis C Elimination in Taiwan: Insights From the Hemodialysis Population

  • by Ming-Yan Jiang, Yi-Chan Lee, Tsung-Hsueh Lu

  • January 29, 2026

Related Content

At the Hart of Pathology

Sitting Down With... John Hart, Professor and Vice Chair of Anatomic Pathology at the University of Chicago Medicine

Lawmakers add ID requirement to Indiana’s needle exchanges

Is Point-of-Care Hepatitis C Virus Testing Too Expensive?

RNA testing carries substantial cost burden for hospitals, study finds

  • January 14, 2026

  • 2 min